Innovative Value and Clinical Implications of OptiTROP-Lung04 Study in EGFR-TKI-Resistant Non-Small Cell Lung Cancer
10.3971/j.issn.1000-8578.2026.26.0012
- VernacularTitle:OptiTROP-Lung04研究在EGFR-TKI耐药非小细胞肺癌中的创新价值与临床启示
- Author:
Zuoyuan TAN
1
;
Yuling ZHONG
1
;
Jingyi WANG
2
;
Lin WU
2
Author Information
1. The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China;Graduate Collaborative Training Base of Hunan Cancer Hospital, University of South China, Hengyang Medical School, Hengyang 421001, China.
2. The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
- Publication Type:SPECIALFEATURE
- Keywords:
Non-small cell lung cancer;
Antibody-drug conjugate;
TROP-2
- From:
Cancer Research on Prevention and Treatment
2026;53(5):325-331
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-drug conjugates (ADCs) have emerged as a standard treatment modality for previously treated driver gene-positive advanced non-small cell lung cancer (NSCLC). Sacituzumab tirumotecan (sac-TMT), a novel TROP-2-targeting ADC, has been the focus of the phase Ⅲ clinical trial OptiTROP-Lung04. This trial demonstrated, for the first time, that single-agent sac-TMT significantly improves progression-free survival and overall survival compared with conventional platinum-based chemotherapy in patients with epidermal growth factor receptor (EGFR) mutant advanced NSCLC following resistance to EGFR tyrosine kinase inhibitors. This review combines existing consensus from literature with the latest research evidence to systematically analyze OptiTROP-Lung04 from multiple perspectives, including molecular mechanisms, study design, clinical significance, and safety management. Furthermore, it explores future development directions in an effort to provide new insights into precision therapy for advanced NSCLC.
